Lancellotti P, Nguyen Trung M L, Sprynger M, Lempereur M, Martinez C
Faculté de Médecine, ULiège, Service de Cardiologie, GIGA Cardiovasculaire, CHU Liège, Belgique.
Service de Cardiologie, CHU Liège, Belgique.
Rev Med Liege. 2020 May;75(5-6):300-303.
Eighteen years after the birth of the concept, TAVI (Transcatheter Aortic Valve Implantation) has established itself as the treatment of choice for symptomatic patients with severe aortic valve stenosis at high surgical risk. Unlike surgical prosthesis, the benefit of which has been validated in observational studies, indications for TAVI are now based on the results of large randomized trials. The TAVI revolution continues today with the miniaturization of the equipment, the development of new closure systems, the availability of a wider range of prosthesis sizes and the growing experience of operators, all contributing to the widening of indications to lower risk patients.
在这一概念诞生18年后,经导管主动脉瓣植入术(TAVI)已成为手术风险高的重度主动脉瓣狭窄症状性患者的首选治疗方法。与手术假体不同,手术假体的益处已在观察性研究中得到验证,而TAVI的适应症现在基于大型随机试验的结果。如今,TAVI革命仍在继续,设备小型化、新型封堵系统的开发、更广泛的假体尺寸选择以及操作人员经验的不断积累,所有这些都有助于将适应症扩大到风险较低的患者。